Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer

[1]  A. Zietman,et al.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. , 2013, European urology.

[2]  D. Grignon,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. , 2013, European urology.

[3]  M. Babjuk,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[4]  K. Guru,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[5]  D. Wood.  Re: Radiotherapy With or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .

[6]  T. Kron,et al.  Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  Arndt Hartmann,et al.  Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer , 2012, BJU international.

[8]  H. Nishiyama,et al.  Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer. , 2012, Japanese journal of clinical oncology.

[9]  Emma Hall,et al.  Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. , 2012, The New England journal of medicine.

[10]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[11]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Efstathiou,et al.  Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. , 2012, The Journal of urology.

[13]  R. Mak,et al.  Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Wood.  Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. , 2011, The Journal of urology.

[15]  F. Burkhard,et al.  Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. , 2011, The Journal of urology.

[16]  Ananya Choudhury,et al.  MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. , 2010, Cancer research.

[17]  H. Sandler,et al.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Ficarra,et al.  Complications and mortality after radical cystectomy for bladder transitional cell cancer. , 2009, The Journal of urology.

[19]  A. Zietman,et al.  Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. , 2009, Urology.

[20]  M. Milowsky,et al.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. , 2009, European urology.

[21]  A. Zietman,et al.  Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. , 2007, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[22]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[23]  D. Grignon,et al.  Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy O , 2005, International journal of radiation oncology, biology, physics.

[24]  A. Zietman,et al.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. , 2003, The Journal of urology.

[25]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[26]  A. Feller,et al.  HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications , 2002, International journal of cancer.

[27]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Grignon,et al.  Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[30]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Donnelly,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.

[32]  L. True,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. True,et al.  Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Sauer,et al.  Organ-sparing treatment of advanced bladder cancer: a 10-year experience. , 1994, International journal of radiation oncology, biology, physics.

[35]  F. Baillet,et al.  Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Shipley,et al.  Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full‐dose irradiation , 1987, Cancer.